News | June 29, 2011

Partnership Brings Together Diabetes, Cardiovascular Testing

June 29, 2011 – An industry-first collaboration is bringing together cardiovascular testing company Atherotech Diagnostics Lab and diabetes testing company GlycoMark. The collaboration means the two companies will jointly commercialize the VAP (vertical auto profile) cholesterol test with the GlycoMark diabetes test.

The VAP test is the only expanded lipid test that routinely reports directly measured LDLc, which is included in the 22 reported cholesterol components — all at no additional cost. The VAP test also identifies markers of metabolic syndrome, often associated with early diabetes.

GlycoMark is a simple blood test used to measure after-meal glucose control in patients with diabetes. GlycoMark can accurately reveal potentially dangerous postprandial fluctuations in blood sugar — associated with the cardiovascular complications of diabetes — that are undetectable by other means, including the hemoglobin A1c (HbA1c) test.

“Just as standard lipid tests miss more than half of all patients at risk for heart disease, HbA1c misses dangerous glucose swings in about 40 percent of Type 2 diabetes patients,” said Michael E. Cobble, M.D., Atherotech Diagnostics Lab chief medical officer. “With diabetes now recognized as a major risk factor for cardiovascular disease, it’s time to recognize the value of well-validated clinical tests to more effectively monitor and treat these two disease states.”

The widely used HbA1c test measures average glucose levels over a two- to three-month period. GlycoMark provides a much more sensitive measure of variation over a one- to two-week period, thus indicating if blood glucose variability that comprises the average is minimal or extreme and whether treatment changes are indicated.

The GlycoMark test has proven particularly effective in patients with HbA1c values of less than eight percent — that is, those whose blood sugars were previously thought to be nearing or in control. GlycoMark is the only blood test proven to detect glycemic variability and hyperglycemic episodes in moderately controlled patients who have Type 1 or Type 2 diabetes mellitus, which affect more than 245 million adults and children worldwide.

“As a diabetologist, I routinely use GlycoMark to provide both the patient and me information we can't get from HbA1c alone,” said Irl B. Hirsch, M.D., professor of medicine at the University of Washington School of Medicine. “Patients appreciate the ability to better understand the ‘quality’ of their HbA1c.”

GlycoMark is a U.S. Food and Drug Administration (FDA)-approved test for monitoring intermediate glycemic control by measuring the levels of a monosaccharide 1,5-anhydroglucitol (1,5- AG) in blood. GlycoMark is being used in clinical practices nationwide and is now also available through Atherotech Diagnostics Lab. The test is also available at most major contract research organizations for pharmaceutical research studies.

Cholesterol components reported by the VAP test include Lp(a), apoB, apoA1, and the apoB/apoA1 ratio, making the VAP test the only lipid profile that routinely reports all three lipid parameters — LDL, non-HDL and apoB — considered necessary by the ADA and the American College of Cardiology. The two companies are co-exhibiting in GlycoMark’s booth #2133 at the 2011 American Diabetes Association (ADA) 71st Scientific Sessions June 24–28 in San Diego.

For more information: www.Atherotech, www.GlycoMark.com

Related Content

Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing| September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Alere point of care POC testing for INR
News | Point of Care Testing| July 17, 2017 | Dave Fornell
July 17, 2017 — Despite issues with point-of-care INR testing company Alere Inc., Abbott announced this week it is on
Siemens Xprecia Stride anticoagulation, coagulation PT/INR or INR testing at the point of care (POC)

Point-of-care coagulation PT/INR testing with handheld devices can help improve outcomes with more convenient and frequent measurements to keep patients within the therapeutic range of anticoagulant agents.

Feature | Point of Care Testing| May 05, 2017 | Nicholas C. Vanderslice, Ph.D., and Arnol S. Rios
Point-of-care (POC) coagulation analyzers that measure prothrombin time/international normalized ratio (PT/INR) on fi
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing| May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
New Blood Test Predicts Major Cardiac Events Better Than Clinical Evaluation of Other Common Risk Factors
News | Blood Testing| April 28, 2017
Prevencio Inc. announced the publication of data demonstrating that a simple new blood test is more accurate than...
New Study Pursues Universal Sample Bank for Troponin Tests
News | Blood Testing| April 13, 2017
April 13, 2017 — A study published recently in the American Association for Clinical Chemistry’s (AACC)...
PTS Diagnostics, FDA 510k clearance, extended HDL range, lipid panel test strips
News | Blood Testing| April 05, 2017
PTS Diagnostics announced that the U.S. Food and Drug Administration (FDA) has cleared an expanded top range for...
highly sensitive troponin testing
News | Cardiac Diagnostics| March 21, 2017
March 21, 2017 — A blood test for a protein called high-sensitivity troponin T, which is released into the bloodstrea
heart attack evaluation, blood test, HEART Score, ER, emergency room, Circulation Cardiovascular Quality and Outcomes study
News | Blood Testing| March 01, 2017
Up to 40 percent of emergency room (ER) patients with chest pain can safely go home in a little under 2 hours, using a...
troponin blood test, heart disease risk, heart attack, British Heart Foundation, BHF
News | Blood Testing| January 04, 2017
A high-sensitivity blood test could be used to predict which patients are at risk of a heart attack according to new...
Overlay Init